GlassScriptPhysician profile
Emil Petrov
NPI 1639139934
$472.69
in general payments reported to CMS, 2019-2025
7 companies · $94.41 in 2025
The $94.41 reported for 2025 was more than what a typical Anatomic Pathology & Clinical Pathology provider received nationally (typical 2025 total: $50.59).
See the full distribution for Anatomic Pathology & Clinical Pathology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $23.82 · 2023: $20.70 · 2024: $334 · 2025: $94.41.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $449.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $448.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $142.08 | 2024-2025 | Ibsrela |
| Janssen Biotech, INC. | $127.47 | 2024 | Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $98.32 | 2024-2025 | Entyvio, Gattex |
| Mml US, INC. | $40.18 | 2025 | Reactiv8 |
| Roche Diagnostics Corporation | $23.82 | 2022 | |
| Intercept Pharmaceuticals, INC. | $20.70 | 2023 | Ocaliva |
| Phathom Pharmaceuticals, INC. | $20.12 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emil Petrov listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.